N/A
Completed N=687
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Source: ClinicalTrials.gov NCT00993915 ↗Enrolled (actual)
687
Serious AEs
0.0%
Results posted
Dec 2012
Primary outcomePrimary: Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit — 51.52 percentage of participants
Summary
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant diseases and cardiovascular risk factor.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit |
51.52 | — |
| SECONDARY Percentage of Participants Achieving LDL Level ≤ 100 mg/dL at the 1 Month Visit |
— | — |
| SECONDARY Change From Baseline in Lipid Parameters |
-98.06; -76.84; 3.15; -70.57 | — |
| SECONDARY Percent Change From Baseline in Lipid Parameters |
-33.57; -40.66; 14.49; -23.05 | — |
Eligibility Criteria
Inclusion Criteria
- Patients, who eligible to sign informed consent;
- Patients with indications to lipid lowing therapy, according to local product document.
- Patients with CHD and high risk of CV complications (Diabetes Mellitus II, Myocardial Infarction, Heart Failure, Arterial Hypertension, ets) will be included into study;
- Patients with LDL levels: > 3,5 mmol/l
Exclusion Criteria
- Individual intolerance of atorvastatin, in accordance to local product document.
Data sourced from ClinicalTrials.gov (NCT00993915). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.